MedTrace Logo

Real-world Study on Adjuvant Octreotide Therapy in pNETs

NCT06080204 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 411

Last updated 2023-10-18

No results posted yet for this study

Summary

Adjuvant therapy in pancreatic neuroendocrine tumors (pNETs) after radical resection lacks evidence-based data and is controversial. Real-world data were clustered to validate whether the long-acting octreotide is a potential candidate for adjuvant therapy in high recurrence risk G2 pNET patients.

Conditions

  • Pancreatic Neuroendocrine Tumor G2

Interventions

DRUG

Octreotide LAR

Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2020-04-30
Completion
2020-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06080204 on ClinicalTrials.gov